DDInter1044 DDInter1676
Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. This drug has also been used in combination with other drugs for the treatment of various cancers. [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranul
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Levamisole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Levamisole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Levamisole {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Levamisole {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Levamisole may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Levamisole may lead to a major life threatening interaction when taken with Infliximab